1145782

Adamas Pharmaceuticals, Inc. — FEI 3007281742

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
June 28, 2021
Fiscal Year
2021
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Emeryville, CA (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
673021 CFR 314.80(b)Failure to develop written procedures